Bharat Parenterals Targets FY27 Rebound Driven by Subsidiary Growth

Bharat Parenterals Ltd (BPL) is positioning FY27 as a recovery year, projecting revenue growth after a 'bridge year' in FY26 focused on regulatory approvals and scaling new business segments. The company ended FY26 with an order book of INR 171 crore.

Reader Takeaway: Regulatory wins at Innoxel and profitability at Varenyam Healthcare offer a turnaround path, but execution risks remain.

What Happened

In FY26, BPL's standalone revenue fell 23% due to exiting low-margin businesses and facility upgrades. However, its subsidiary Innoxel narrowed its EBITDA loss by INR 23.5 crores and achieved its first EBITDA-positive quarter in Q4 FY26. Innoxel also secured US FDA clearance and EU GMP certification, paving the way for commercial supply to the US and European markets in FY27. Another subsidiary, Varenyam Healthcare, turned profitable with a 13.7% revenue increase to INR 58.4 crores.

Why It Matters

The successful regulatory clearances for Innoxel are crucial for BPL to enter lucrative US and European markets. The turnaround of subsidiaries, moving from losses to profitability or positive EBITDA, is expected to improve consolidated earnings and restore investor confidence after previous financial misses. Management has provided conservative guidance for FY27, aiming to meet targets after prior shortfalls.

The Backstory

FY26 was intentionally a 'bridge year' for Bharat Parenterals, with a strategic focus on achieving regulatory milestones rather than immediate revenue expansion. This followed a period where the company's standalone revenue faced challenges.

What Changes Now

With regulatory approvals in hand, Innoxel is set to commence commercial supplies to the US and Europe in FY27. The company projects revenue growth of 35% to 45% and EBITDA margins of 20% to 25%, with an anticipated INR 70-90 crores in out-licensing income. Varenyam Healthcare is expected to continue its growth trajectory with 20% to 25% revenue expansion and 8% to 13% EBITDA margins. Varenyam Bio's facility commissioning is planned for September 2027, with commercial supply expected in Q4 FY29.

Risks to Watch

Bharat Parenterals anticipates minor operational disruptions in FY27 due to scheduled regulatory inspections (PIC/S and EU GMP) at its standalone facilities. Geopolitical issues have caused a three-month delay in Varenyam Bio's timeline. The domestic business faces revenue concentration risk, with the top five brands contributing about 50% of its revenue.

Context Metrics

• FY26 Standalone Revenue Decline: 23%
• Innoxel EBITDA Loss Reduction (FY26): INR 23.5 crores
• Varenyam Healthcare Revenue (FY26): INR 58.4 crores (+13.7% YoY)
• FY27 Order Book: INR 171 crores
• Innoxel Out-licensing Income Projection (FY27): INR 70-90 crores

What to Track Next

Investors will closely watch BPL's ability to execute its FY27 guidance, particularly the ramp-up of Innoxel's commercial supplies in regulated markets and the successful navigation of upcoming regulatory inspections.